A phase III study of tarenflurbil spray for the treatment of skin diseases.

Trial Profile

A phase III study of tarenflurbil spray for the treatment of skin diseases.

Planning
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2016

At a glance

  • Drugs Tarenflurbil (Primary)
  • Indications Skin disorders
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 22 Jan 2016 New trial record
    • 12 Dec 2008 According to a MIKA Pharma GmbH media release, phase III proof-of-concept trial will be finance by GALEN pharma.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top